Equillium Valuation

EQ Stock  USD 1.57  0.03  1.88%   
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Equillium shows a prevailing Real Value of $1.81 per share. The current price of the firm is $1.57. Our model computes the value of Equillium from reviewing the firm fundamentals such as Operating Margin of (5.55) %, shares outstanding of 60.89 M, and Shares Owned By Insiders of 20.90 % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Equillium's valuation include:
Price Book
3.1491
Enterprise Value
65.1 M
Enterprise Value Ebitda
0.0666
Price Sales
22.1833
Forward PE
1.5314
Undervalued
Today
1.57
Please note that Equillium's price fluctuation is extremely dangerous at this time. Calculation of the real value of Equillium is based on 3 months time horizon. Increasing Equillium's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Equillium's intrinsic value may or may not be the same as its current market price of 1.57, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  1.57 Real  1.81 Target  2.5 Hype  1.51
The intrinsic value of Equillium's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Equillium's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
1.81
Real Value
9.32
Upside
Estimating the potential upside or downside of Equillium helps investors to forecast how Equillium stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Equillium more accurately as focusing exclusively on Equillium's fundamentals will not take into account other important factors:
Earnings
Estimates
LowProjectedHigh
-0.06-0.06-0.06
Details
Hype
Prediction
LowEstimatedHigh
0.081.519.02
Details
2 Analysts
Consensus
LowTarget PriceHigh
2.282.502.78
Details
Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Equillium's intrinsic value based on its ongoing forecasts of Equillium's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Equillium's closest peers.

Equillium Cash

30.74 Million

Equillium Total Value Analysis

Equillium is currently projected to have takeover value of 65.05 M with market capitalization of 97.43 M, debt of 384 K, and cash on hands of 57.56 M. Please note that takeover value may be misleading and is a subject to accounting mistakes. We encourage investors to methodically examine all of the Equillium fundamentals before making investment evaluation based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
65.05 M
97.43 M
384 K
57.56 M

Equillium Investor Information

About 21.0% of the company shares are held by company insiders. The book value of Equillium was currently reported as 0.51. The company recorded a loss per share of 0.59. Equillium had not issued any dividends in recent years. Equillium is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.

Equillium Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Equillium has an asset utilization ratio of 160.5 percent. This connotes that the Company is making $1.61 for each dollar of assets. An increasing asset utilization means that Equillium is more efficient with each dollar of assets it utilizes for everyday operations.
 
Covid
 
Interest Hikes

Equillium Profitability Analysis

Taking into consideration Equillium's profitability measurements, Equillium may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Equillium's ability to earn profits and add value for shareholders.
 
Net Loss  
First Reported
2017-06-30
Previous Quarter
-5.7 M
Current Value
-4.2 M
Quarterly Volatility
6.8 M
 
Covid
 
Interest Hikes
As of 02/14/2026, Gross Profit is likely to grow to about 49.6 M, while Pretax Profit Margin is likely to drop (0.18).
For Equillium profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Equillium to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Equillium utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Equillium's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Equillium over time as well as its relative position and ranking within its peers.

Equillium Earnings per Share Projection vs Actual

By analyzing Equillium's earnings estimates, investors can diagnose different trends across Equillium's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Equillium is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
 
Interest Hikes
Equillium is projected to generate -0.06 in earnings per share on the 31st of March 2026. Equillium earnings estimates show analyst consensus about projected Equillium EPS (Earning Per Share). It derives the highest and the lowest estimates based on Equillium's historical volatility. Many public companies, such as Equillium, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm.

Equillium Ownership Allocation

Equillium holds a total of 60.89 Million outstanding shares. Over half of Equillium's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Equillium Profitability Analysis

The company generated the yearly revenue of 41.09 M. Annual Net Loss to common stockholders was (8.07 M) with gross profit of 4.39 M.

About Equillium Valuation

The stock valuation mechanism determines Equillium's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Equillium based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Equillium. We calculate exposure to Equillium's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Equillium's related companies.
Last ReportedProjected for Next Year
Gross Profit47.3 M49.6 M
Pretax Profit Margin(0.17)(0.18)
Operating Profit Margin(0.18)(0.19)
Net Loss(0.18)(0.19)

Equillium Growth Indicators

Investing in growth stocks can be very risky. If the company such as Equillium does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Common Stock Shares Outstanding35.4 M
Forward Price Earnings1.5314

Equillium Current Valuation Indicators

Equillium's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Equillium's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Equillium, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Equillium's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Equillium's worth.

Additional Tools for Equillium Stock Analysis

When running Equillium's price analysis, check to measure Equillium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Equillium is operating at the current time. Most of Equillium's value examination focuses on studying past and present price action to predict the probability of Equillium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Equillium's price. Additionally, you may evaluate how the addition of Equillium to your portfolios can decrease your overall portfolio volatility.